uniQure N.V. (NASDAQ: QURE) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On December6, 2018, we signed an amendment to the Second Amended and Restated Loan and Security Agreement with Hercules Technology Growth Capital Inc. (“Hercules”) that both refinanced our existing $20 million credit facility and provided us with an additional commitment of $30 million (of which $15 million is subject to the discretion of Hercules) (the “Amended Facility”). At signing, we drew down an additional $15 million. We are able to draw another $15 million through June30, 2020 subject to the terms of the Amended Facility.

The Amended Facility extends the loan’s maturity date until June1, 2023. This includes extending the interest-only period from November2018 to January1, 2021, or in the event that we raise more than $90 million in a corporate transaction public offering or complete a phase 3 pivotal study of AMT-061 in patients with Hemophilia B with clinical results that support a new drug application with the U.S. Food and Drug Administration, to January1, 2022. We are required to repay the facility in equal monthly installments of principal and interest between the end of the interest-only period and the maturity date. The interest rate continues to be adjustable and is the greater of (i)8.85% or (ii)8.85% plus the prime rate less 5.50%. Under the Amended Facility, we have paid a facility fee of 0.50% of the $35,000,000 outstanding as of signing and will owe a back-end fee of 4.95% of the outstanding debt.

The foregoing summary of the Amended Facility does not purport to be complete and is qualified in its entirety by reference to the Amended Facility, which is attached as Exhibit10.1 to this Form8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits